PRESS RELEASE

Half year report on Adocia’s liquidity agreement with Kepler Capital Markets

Lyon, France, July 10, 2014 – Under the liquidity agreement entrusted by Adocia to Kepler Capital Markets, the following assets appeared on the liquidity account as at June 30, 2014:

- 18,875 shares of Adocia and
- 233,973.09 euros in cash.

At the latest report dated on December 31, 2013 with DSF Markets, the following assets appeared on the liquidity account:

- 40,326 shares of Adocia and
- 215,305.78 euros in cash.

As a reminder, the liquidity agreement with DSF Markets signed on March 14, 2012 was terminated by Adocia on April 30, 2014. The company announced that a liquidity agreement was signed on May 19, 2014 with Kepler Capital Markets. At that time, the following resources have been allocated to the liquidity account: 15,026 Adocia shares and 300,000 euros in cash.

About Adocia

To be a global leader in the delivery of insulins and therapeutic proteins

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. Adocia’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

Adocia has successfully completed two Phase I and II studies of a fast-acting human insulin formulation, two Phase I and II studies of an ultra-fast-acting insulin lispro and a Phase I/II of a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog. Dose-escalation Phase IIa studies of all three products are scheduled for the third and the fourth quarter 2014.

The company has also obtained positive results in a Phase I/II study of a diabetic-foot-ulcer-healing product based on PDGF-BB (Platelet-Derived Growth-Factor BB). A phase III clinical trial dossier has been filed with Indian regulatory authorities, and the trial is expected to start at the beginning of the third quarter 2014.
Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). Adocia is engaged in collaborative programs with two major pharmaceutical companies in this field.

**Fighting cancer with targeted treatments**

DriveIn® is a nanotechnology which is remarkably efficient in delivering active compounds into cancer cells. This new platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

**“Innovative medicine for everyone, everywhere”**

Adocia’s therapeutic innovations aim at providing solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

Adocia is listed on the regulated market of Euronext Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and its share price is included in the Next Biotech index. American Depositary Receipts representing Adocia common stock are traded on the US OTC market under the ticker symbol ADOCY. For more information, visit [www.adocia.com](http://www.adocia.com)

**Contact**

Gerard Soula - contactinvestisseurs@adocia.com
Chairman and CEO of Adocia
Tel.: +33 4 72 610 610

**Press Relations**

ALIZE RP
Caroline Carmagnol
caroline@alizerp.com
adocia@alizerp.com
Tel.: +33 170 225 390